Candida Yates has been appointed a Founding Scholar of the British Psychoanalytic Council. This is in recognition of her significant contribution to academic research in the area and beyond. The BPC is the professional registration body for the UK’s leading psychoanalytical practitioners. Up until recently, affiliations were open solely to qualified clinicians trained in the practice of psychoanalysis, psychoanalytical psychotherapy, and psychodynamic psychotherapy.
This newly created category expands the BPC’s purview by recognising the enormous contribution that academics and scholars have made to the study of psychoanalysis through research and publication. Being a Founding Scholar can open up further opportunities for debate, collaboration and knowledge exchange between the BPC, academia and beyond. The launch event was held at the Freud Museum in London on 21st February 2019.
As a Founding Scholar, Candida has now been invited to join the new organising committee for BPC Scholars to shape this new and exciting association going forward. She has also been invited to join the Editorial board of their members magazine ‘New Associations’: https://www.bpc.org.uk/new-associations.
BU’s Sascha Dov Bachmann appointed Reviewer to The Estonian Research Council (ETAg)
Conference: Powerplay: Psychoanalysis and Political Culture; BU at the Freud Museum, 10th December










BU academic publishes in online newspaper in Nepal
Final day of the ESRC Festival of Social Science
Using Art to enhance Research
Register now to attend the 17th Annual Postgraduate Research Conference – Wednesday 3 December 2025
Portrait Concert featuring BU academic at L’Espace du Son Festival 2025, Brussels
ECR Funding Open Call: Research Culture & Community Grant – Application Deadline Friday 12 December
MSCA Postdoctoral Fellowships 2025 Call
ERC Advanced Grant 2025 Webinar
Horizon Europe Work Programme 2025 Published
Horizon Europe 2025 Work Programme pre-Published
Update on UKRO services
European research project exploring use of ‘virtual twins’ to better manage metabolic associated fatty liver disease